Adaptive Biotechnologies
ADPT
27.93
-0.12
-0.43%
Adaptive Biotechnologies
US · ADPT
#2184 by market cap
Listed 2019
27.93
-0.12
-0.43%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5Market Newswire · 2026/11/5
-
Rating change
Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $22Market Newswire · 2026/6/29
-
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/11/10
-
J.P. Morgan Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/11/9
-
Rating change
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $27Market Newswire · 2026/10/13
-
Rating change
William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy RatingMarket Newswire · 2026/6/17
-
Rating change
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32Market Newswire · 2026/10/13
-
Rating change
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Raises Target Price to $27Market Newswire · 2026/10/12
-
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/11/6
-
Rating change
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $27.5Market Newswire · 2026/8/4
-
Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $25 to $28Market Newswire · 2026/7/31
-
Rating change
Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32Market Newswire · 2026/10/1
-
Rating change
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34Market Newswire · 2026/9/22
-
Rating change
Goldman Sachs Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $35Market Newswire · 2026/9/29
-
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34Market Newswire · 2026/11/5
-
Rating change
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $24Market Newswire · 2026/7/23
-
Rating change
J.P. Morgan Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $30Market Newswire · 2026/10/14
-
Rating change
TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/7/15
-
Rating change
Craig-Hallum Maintains Adaptive Biotechnologies(ADPT.US) With Buy RatingMarket Newswire · 2026/9/18
-
Rating change
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Cuts Target Price to $13.54Market Newswire · 2026/5/12
-
Rating change
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/5/12
-
Rating change
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5Market Newswire · 2026/8/24
-
Rating change
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)TipRanks · 2026/5/12
-
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34Market Newswire · 2026/9/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Adaptive Biotechnologies discussion 0 comments